Trial · NCT03261947
Results by group175
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 175
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Dose Limiting Toxicities (DLTs) in Western Safety Cohort | Western Safety Cohort | 50 | percentage of participants | ||
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort | Western Safety Cohort | TEAEs | 100 | percentage of participants | |
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort | Western Safety Cohort | SAEs | 58.3 | percentage of participants | |
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort | Western Safety Cohort | TEAEs Leading to Dose Modifications | 33.3 | percentage of participants | |
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort | Western Safety Cohort | TEAEs Leading to Treatment Discontinuation | 8.3 | percentage of participants | |
| Disease Control Rate (DCR) in Tumor-Specific Cohorts | Pancreatic Cancer Cohort | 46.2 | 26.4 to 66.9 | percentage of participants | |
| Disease Control Rate (DCR) in Tumor-Specific Cohorts | Metastatic CRC Cohort | 51.6 | 38.7 to 64.3 | percentage of participants | |
| Disease Control Rate (DCR) in Tumor-Specific Cohorts | sqEC Cohort | 52.6 | 35.8 to 69.0 | percentage of participants | |
| Disease Control Rate (DCR) in Tumor-Specific Cohorts | sqNSCLC Cohort | 58.8 | 40.6 to 75.4 | percentage of participants | |
| Cmax: Maximum Observed Plasma Concentration for TAK-931 | Western Safety Cohort | Cycle 1 Day 1 | 173.61 | Standard Deviation 59.677 | ng/mL |
| Cmax: Maximum Observed Plasma Concentration for TAK-931 | Pancreatic Cancer Cohort | Cycle 1 Day 1 | 204.69 | Standard Deviation 90.527 | ng/mL |
| Cmax: Maximum Observed Plasma Concentration for TAK-931 | Metastatic CRC Cohort | Cycle 1 Day 1 | 185.46 | Standard Deviation 61.158 | ng/mL |
| Cmax: Maximum Observed Plasma Concentration for TAK-931 | Western Safety Cohort | Cycle 1 Day 8 | 196.17 | Standard Deviation 73.702 | ng/mL |
| Cmax: Maximum Observed Plasma Concentration for TAK-931 | Pancreatic Cancer Cohort | Cycle 1 Day 8 | 180.55 | Standard Deviation 75.036 | ng/mL |
| Cmax: Maximum Observed Plasma Concentration for TAK-931 | Metastatic CRC Cohort | Cycle 1 Day 8 | 216.18 | Standard Deviation 121.488 | ng/mL |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 | Western Safety Cohort | Cycle 1 Day 1 | 1.57 | Full Range 0.8 to 2.2 | hour |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 | Pancreatic Cancer Cohort | Cycle 1 Day 1 | 2.00 | Full Range 0.5 to 6.3 | hour |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 | Metastatic CRC Cohort | Cycle 1 Day 1 | 1.85 | Full Range 0.9 to 6.0 | hour |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 | Western Safety Cohort | Cycle 1 Day 8 | 1.59 | Full Range 1.0 to 4.0 | hour |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-931 | Pancreatic Cancer Cohort | Cycle 1 Day 8 | 2.00 | Full Range 1.0 to 4.3 | hour |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03261947/results